Purple Biotech (PPBT) vs PRF Technologies (PRFX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Purple Biotech is the larger company by market cap ($1.9 million vs $1.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PPBT | PRFX |
|---|---|---|
| Share price | $1.53 | $0.4758 |
| Market cap | $1.86M | $1.66M |
| 1-day change | -4.09% | -23.68% |
| EPS (TTM) | $-47.64 | $-4.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $17.00K |
| Net income (latest FY) | $-26.39M | $-5.02M |
| Gross margin | — | -311.76% |
| Operating margin | — | -30129.41% |
| Net margin | — | -29541.18% |
| 52-week high | $8.90 | $7.95 |
| 52-week low | $0.91 | $0.46 |
| Distance from 52-week high | -82.87% | -94.02% |
| Analyst consensus | none | — |
| Avg. price target upside | +1014.75% | — |
| Average volume | 1.26M | 228.55K |
| Shares outstanding | 1.22M | 3.50M |
| Employees | 10 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Purple Biotech
PPBT stock →Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
About PRF Technologies
PRFX stock →PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
PPBT vs PRFX FAQ
Which is bigger, Purple Biotech or PRF Technologies?
Purple Biotech (PPBT) is larger, with a market capitalization of $1.86M compared with $1.66M for PRF Technologies (PRFX).
Are Purple Biotech and PRF Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.